润都股份（002923）(002923.SZ)发布公告，公司近日收到国家药品监督管理局签发的《药品注册证 书》，涉及药品：缬沙坦氨氯地平片(I)。本品适用于治疗原发性高血压。本品用于单药治疗不能充分控 制血压的患者。 ...

智通财经APP讯，润都股份(002923.SZ)发布公告，公司近日收到国家药品监督管理局签发的《药品注册 证书》，涉及药品：缬沙坦氨氯地平片(I)。本品适用于治疗原发性高血压。本品用于单药治疗不能充分 控制血压的患者。 ...

Core Viewpoint - The company, Huayuan Biological, reported a revenue of 635 million yuan for the first half of 2025, marking a year-on-year growth of 5.86%, with a net profit attributable to shareholders of 162 million yuan, up 13.67% year-on-year, and a net cash flow from operations of 275 million yuan, increasing by 47.68% [1] Group 1: Financial Performance - The company achieved an operating income of 635 million yuan in H1 2025, reflecting a 5.86% increase compared to the previous year [1] - The net profit attributable to shareholders reached 162 million yuan, representing a year-on-year growth of 13.67% [1] - The net profit excluding non-recurring items was 150 million yuan, showing a significant increase of 37.36% year-on-year [1] - The net cash flow from operating activities was 275 million yuan, which is a 47.68% increase compared to the same period last year [1] Group 2: Business Segments - Huayuan Biological operates primarily in two segments: vitamins and pharmaceutical manufacturing [1] - The company has completed the full industrial chain layout for Vitamin D3, becoming the only global producer with such a capability [1] - In the vitamin segment, key products include cholesterol from lanolin, Vitamin D3, 25-hydroxy Vitamin D3, and Vitamin A [1] - The pharmaceutical manufacturing segment focuses on high-tech barrier formulation products for chronic diseases, with major products including Valsartan Amlodipine Tablets and Levofloxacin Tablets [2] Group 3: Research and Development - The company has established three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrial research, and chemical automation [1] - In the pharmaceutical segment, Huayuan Pharmaceutical has a dedicated R&D center and is advancing new product development with a strategy of "producing one generation, researching one generation, and reserving one generation" [2] - The company is actively developing new products and optimizing existing processes to enhance production efficiency and core competitiveness [1][2]

Core Viewpoint - The company is navigating a challenging external environment while focusing on strategic reforms and innovations to enhance its competitive position in the pharmaceutical industry, particularly in the context of aging population and healthcare demands [3][5][6]. Company Overview - The company is engaged in the pharmaceutical industry, emphasizing traditional Chinese medicine and innovative drug development [3][10]. - The company has a strategic focus on becoming a leader in elderly health management and chronic disease management, leveraging its established brand and product resources [6][7]. Financial Performance - The company experienced a decline in revenue and net profit during the reporting period due to external challenges such as intensified competition and policy impacts [5]. - Despite the short-term performance pressure, the company is committed to long-term growth through strategic reforms and channel transformations [5][6]. Industry Analysis - The Chinese pharmaceutical industry is benefiting from a large population base, a broad domestic market, and increasing innovation capabilities, which enhance its international competitiveness [3]. - Recent government policies are supportive of innovative drug development, aiming to create a globally competitive ecosystem for the pharmaceutical industry [3][4]. Market Trends - The aging population is driving demand for healthcare services, creating a significant market opportunity for the company [6][7]. - The retail pharmaceutical sector is undergoing consolidation, with a shift towards online purchasing channels impacting traditional sales models [4][5]. Strategic Initiatives - The company is actively participating in national drug procurement programs to enhance its market presence and product accessibility [8][9]. - The company is focusing on brand enhancement and marketing strategies to strengthen its core product lines and expand its market reach [9][11]. Research and Development - The company is advancing its R&D efforts in the field of elderly health and chronic disease management, with a focus on natural and plant-based medicines [12]. - Several innovative drug projects are progressing, including those targeting ischemic stroke and non-alcoholic fatty liver disease, which are expected to meet significant clinical needs [12][13]. Global Expansion - The company is pursuing international market opportunities, having submitted numerous overseas registration applications and successfully obtaining product approvals in multiple countries [13]. - The company is also engaging in international collaborations to enhance its global footprint and contribute to global health initiatives [13].